| Autor: |
J P, Gendre, J Y, Mary, C, Florent, R, Modigliani, J F, Colombel, J C, Soulé, J P, Galmiche, E, Lerebours, L, Descos, J M, Viteau |
| Rok vydání: |
1993 |
| Předmět: |
|
| Zdroj: |
Gastroenterology. 104(2) |
| ISSN: |
0016-5085 |
| Popis: |
Mesalamine provides a new therapeutic approach in treating Crohn's disease.To assess the efficacy and safety of slow-release mesalamine (Pentasa; Ferring AS, Vanløse, Denmark) in maintaining remission in Crohn's disease, 161 patients with inactive disease were randomized to receive either Pentasa (2 g/day) or placebo in a 2-year double-blind, multicenter trial. Two strata were defined according to the duration of their remission:3 months (n = 64) or 3-24 months (n = 97), presumed to be high and a low relapse risk strata, respectively.The probability of relapse was higher in the short-remission placebo group than in the three other groups (P0.003), showing there was a significant benefit from Pentasa in the high relapse risk stratum. In this stratum, the 2-year ongoing remission rate was of 29% +/- 9% and 45% +/- 11% (mean +/- SD) in the placebo and Pentasa groups, respectively. The incidences of side effects were similar in both groups.Pentasa (2 g/day for 2 years) is a safe and effective maintenance treatment for Crohn's disease when given within 3 months of achieving remission. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
